Gastric Cancer
Conditions
Brief summary
To investigate the feasibility, safety and tolerability of Preoperative Chemoradiation in Patients With Localized Gastric Cancer. Primary endpoint: R0 resection rate. Secondary endpoint: resection rate, pathological complete regression (pCR), effectiveness and safety of regime, disease free survival(DFS) and overall survival(OS).
Detailed description
The prognosis of gastric cancer is poor partially due to low R0 resection rate. Neoadjuvant chemoradiotherapy was reported to be effective in this setting by several phase II studies. The investigators aim to evaluate the efficacy and toxicity of neoadjuvant chemoradiotherapy in a prospective phase II study.
Interventions
RADIATIONS1，oxaliplatin，radiation
Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1.18 ≤ age ≤ 70, Male or Female; 2.Minimum life expectancy of 6 months; 3.Patients with localized, histologically confirmed gastric or gastroesophageal adenocarcinoma; 4.Patients must have a performance status of \< 2 Eastern Cooperative Oncology Group (ECOG); 5.No prior major surgery of the stomach or radiation therapy to the stomach or immunotherapy or chemotherapy; 6.CT or MRI, endorectal ultrasonography (EUS), laparoscopic exploration are required to stage; 7.Without other benign diseases such as lung, kidney, liver infections; 8.Without participating other clinical trials; 9.Patient must sign an informed consent prior to study entry; 10.Patients must have adequate bone marrow function (defined as peripheral absolute granulocyte count of \>1,500/µL, and platelet count of \> 100,000/µL), adequate liver function (bilirubin \<= 1.5 mg/dl), and adequate renal function (creatinine \<= 1.5 mg/dl). 11)Patients without cardiac disease , severe uncontrolled diabetes, hypertension, cerebrovascular disease, or infection.
Exclusion criteria
1. Pregnant women are excluded from study entry due to the potential teratogenic effects of the study treatment; 2. Female patients who planed to have a baby; 3. Prior radiation therapy to the stomach, liver or kidney; 4. Dysfunction of important organs such as liver, kidney or heart; 5.Abnormalities of mental status; 6.Active coronary artery disease; 7.Cardiac arrhythmia, and need to receive medication therapy; 8.Severe uncontrolled hypertension; 9.Active clinical serious infection; 10.The known human immunodeficiency virus (HIV) infection history; 11.The known central nervous system diseases, including brain metastatic tumors; 12.Patients have had clinical clear gastrointestinal bleeding in 6 months; 13.Drug abuse; 14.Swallowing difficulties for drugs; 15.Poor compliance; 16.Presence of concurrent or previous malignancies (except for cervical carcinoma in situ or basal cell carcinoma of the skin); 17.Presence of peritoneal metastasis, distant organs or lymph nodes metastasis; 18.Presence history of major surgery in the past three months; 19.Poor tolerability; 20.Prior history of medication; 21.allergy for chemotherapeutic drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate | 6-8 Weeks | 6-8 weeks after Radiation therapy，we evaluate the lesion，if it is resectable，we will give surgical therapy， |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| safety and tolerability of the treatment regimen | up to 10 weeks | after neoadjuvant chemotherapy and chemoradiotherapy，we evaluate the side effects , and record the side effects |
Other
| Measure | Time frame | Description |
|---|---|---|
| resection rate | 6-8 Weeks | 6-8 weeks after Radiation therapy，we evaluate the lesion，if it is resectable，we will give surgical therapy， |
| disease-free survival | up to 36 months | after surgical therapy，we followup the patients and stat the recurrence and death and calculate the disease-free survival |
| over-all survival | up to 36 months | after surgical therapy，we followup the patients and stat the recurrence and death and calculate the over-all survival |
Countries
China
Contacts
Primary ContactGuichao Li, MD
Backup ContactXiaowen Liu, MD
Outcome results
None listed